Tag: ContraFect

April 14, 2019

5 Top Weekly NASDAQ Biotech Stocks: PhaseBio Gets Breakthrough Therapy Designation

Vital Therapies, Precipio, Chimerix, ContraFect and PhaseBio Pharmaceuticals were last week's top gainers.
December 2, 2018

5 Top Weekly NASDAQ Biotech Stocks: Arsanis Gains 271 Percent

Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers.
July 27, 2018

ContraFect Prices $10 Million Public Offering of Common Stock

ContraFect (NASDAQ:CFRX) has announced the pricing of its underwritten public offering of five million shares of its common stock at...
March 15, 2018

ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

ContraFect (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant...
July 20, 2017

ContraFect Prices Public Offering

ContraFect priced its upcoming public offering of common stock and warrants at $40 million.
May 25, 2017

ContraFect Kicks Off Phase 2 Study

ContraFect began a Phase 2 study to evaluate CF-301 as a treatment of Staphylococcus aureus bacteremia.
March 13, 2017

ContraFect's CEO To Go On Medical Leave

ContraFect (NASDAQ: CFRX) announced that CEO Dr. Steven C. Gilman will take a medical leave starting on March 16.